Orchid Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 20, 2025. Further, the company has informed the Exchange regarding voting results.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma has filed the voting results of its 32nd AGM held on September 20, 2025, conducted via video conferencing. All 9 resolutions were passed, including adoption of FY25 audited financial statements, re-appointment of Mr. Arjun Dhanuka, ratification of cost auditor and appointment of secretarial auditor, and re-appointment of three independent directors. Notably, resolution 8 — modifying the use of funds raised through a Qualified Institutions Placement (QIP) — saw 13.74% dissent, with public institutions voting 65.43% against it. The re-appointment of three independent directors (special resolutions) saw around 9% overall dissent, with public institutions voting about 42-43% against each. A material related party transaction with Otsuka Chemicals (India) Pvt Ltd was approved with 99.99% support, excluding Dhanuka Laboratories' 3.54 crore votes as a related party.
Routine AGM disclosure with all resolutions cleared, but the strong institutional pushback on the QIP fund-utilisation change and independent director re-appointments may signal some shareholder concern worth tracking going forward. No immediate price catalyst, though the related-party transaction approval is now on record.